Correction: Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance (Molecular Cancer Therapeutics (2009) 8, (2086-95))

摘要

In this article (Mol Cancer Ther 2009;8:2086-95), which was published in the August 2009 issue of Molecular Cancer Therapeutics (1), the compound eribulin mesylate was misspelled as erublin mesylate. The online version has been corrected and no longer matches the print version. The author regrets this error.